Indivior opens up a $30M R&D center; Lilly strikes discovery deal with Topas
⇨ Eli Lilly $LLY has turned to Germany’s Topas Therapeutics for a new discovery deal covering drugs for inflammatory or autoimmune conditions. As part of the deal package Tops will get R&D support from the pharma giant while Lilly gets an option on the drugs the partners find. Terms weren’t discussed. Topas CEO Timm Jessen said: “We expect this work to support the value of our approach in inducing tolerance also against external antigens. Additionally, the interest from such an important pharmaceutical company in our technology, we believe, supports the strong commercial potential of our work.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.